TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Microbiol Spectr. 2023 Feb 14;11(1):e0497422. doi: 10.1128/spectrum.04974-22. Epub 2023 Jan 23.
We identified an amino-benzothiazole scaffold from a whole-cell screen against recombinant Mycobacterium tuberculosis under expressing the essential signal peptidase LepB. The seed molecule had 2-fold higher activity against the LepB hypomorph. Through a combination of purchase and chemical synthesis, we explored the structure-activity relationship for this series; 34 analogs were tested for antitubercular activity and for cytotoxicity against eukaryotic cells. We identified molecules with improved potency and reduced cytotoxicity. However, molecules did not appear to target LepB directly and did not inhibit protein secretion. Key compounds showed good permeability, low protein binding, and lack of CYP inhibition, but metabolic stability was poor with short half-lives. The seed molecule showed good bactericidal activity against both replicating and nonreplicating bacteria, as well as potency against intracellular M. tuberculosis in murine macrophages. Overall, the microbiological properties of the series are attractive if metabolic stability can be improved, and identification of the target could assist in the development of this series. Mycobacterium tuberculosis, the causative agent of tuberculosis, is a serious global health problem requiring the development of new therapeutics. We previously ran a high-throughput screen and identified a series of compounds with antitubercular activity. In this paper, we test analogs of our hit molecules for activity against M. tuberculosis, as well as for activity against eukaryotic cells. We identified molecules with improved selectivity. Our molecules killed both replicating and nonreplicating bacteria but did not work by targeting protein secretion.
我们从针对表达必需信号肽酶 LepB 的重组结核分枝杆菌的全细胞筛选中鉴定出一种氨基苯并噻唑支架。种分子对 LepB 低聚物的活性提高了 2 倍。通过购买和化学合成相结合,我们探索了该系列的结构-活性关系;测试了 34 种类似物的抗结核活性和对真核细胞的细胞毒性。我们确定了具有提高的效力和降低的细胞毒性的分子。然而,这些分子似乎并没有直接针对 LepB,也没有抑制蛋白质分泌。关键化合物表现出良好的渗透性、低蛋白结合和缺乏 CYP 抑制,但代谢稳定性差,半衰期短。种分子对复制和非复制细菌均表现出良好的杀菌活性,并且对鼠巨噬细胞中的结核分枝杆菌具有效力。总的来说,如果可以提高代谢稳定性,该系列的微生物特性很有吸引力,如果可以确定靶标,则有助于该系列的开发。结核分枝杆菌是结核病的病原体,是一个严重的全球健康问题,需要开发新的治疗方法。我们之前进行了高通量筛选,鉴定出了一系列具有抗结核活性的化合物。在本文中,我们测试了我们的命中分子的类似物对结核分枝杆菌的活性,以及对真核细胞的活性。我们确定了具有提高选择性的分子。我们的分子既能杀死复制细菌也能杀死非复制细菌,但不是通过靶向蛋白质分泌起作用的。